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Arrhythmogenic Right Ventricular Cardiomyopathy 
(ARVC): ICDs Save Lives & Antitachycardia Pacing 
(ATP) is Highly Successful Regardless of Heart Rate
Of 137 patients enrolled in a prospective North American 
ARVC registry, 108 received implantable cardioverter defibril-
lators (ICDs); 48 had 502 sustained episodes of ventricular 
arrhythmias (VAs) (489 monomorphic and 13 polymorphic). In 
the ICD patients, independent predictors of VAs in follow-up 
included spontaneous sustained VAs before ICD implantation 
and T-wave inversions inferiorly. The only independent predic-
tor for life-threatening VAs, defined as sustained ventricular 
tachycardia (VT) ≥240 beats/min or ventricular fibrillation, was 
a younger age at enrollment. Anti-tachycardia pacing (ATP), 
independent of VT cycle length, was successful in terminating 
92% of VT episodes. The authors concluded that in ARVC 
most VAs at follow-up are monomorphic. Risk factors for VAs 
were spontaneous VAs before enrollment and a younger age 
at ICD implantation. ATP is highly successful in terminating 
VT, and all ICDs should be programmed for ATP, even for 
rapid VT (Link M et al, J Am Coll Cardiol 2014;64:119-125).
PREVAIL: Left Atrial Appendage (LAA) Occlusion 
a Reasonable Alternative to Warfarin for Stroke 
Prevention in Non-Valvular Atrial Fibrillation?
In the PROTECT AF trial in patients with nonvalvular 
atrial fibrillation (NVAF), LAA occlusion with the Watchman 
device was noninferior to warfarin for stroke prevention, but 
procedural safety was questionable. The PREVAIL study 
further assessed efficacy and safety of this device in patients 
with NVAF who had a CHADS2 score ≥1-2. At 1½ years, the 
rate of first primary efficacy endpoint (composite of stroke, 
systemic embolism [SE], and cardiovascular/ unexplained death) 
was 0.064 in the device group (n=269) vs 0.063 in the control 
group (n=138) and did not achieve noninferiority criteria. The 
rate for the second primary efficacy endpoint (stroke or SE 
>7 days post-randomization) was 0.0253 vs 0.0200 (risk dif-
ference 0.0053), achieving noninferiority. Early safety events 
occurred in 2.2% of the device arm (lower than in PROTECT 
AF). All adverse effects were lower in PREVAIL trial than in 
PROTECT AF (4.2% vs 8.7%; p = 0.004). Pericardial effusions 
requiring surgery decreased from 1.6% to 0.4% (p= 0.027), 
and those requiring peri-cardiocentesis decreased from 2.9% 
to 1.5% (p=NS). The authors concluded that LAA occlusion 
was noninferior to warfarin for ischemic stroke prevention or 
SE >7 days post-procedure. Noninferiority was not achieved 
for overall efficacy but procedural safety improved (Holmes 
DR et al, J Am Coll Cardiol 2014;64:1-12).
SCAAR: New-Generation Drug Eluting Stents (DES) 
in STEMI Patients Undergoing PCI are Safe in Short- 
and Long-Term Follow-up, with a Lower Risk of Early/ 
Late Stent Thrombosis and a Low Risk of Very Late 
Stent Thrombosis, Similar to Bare Metal Stents (BMS)
In patients with acute ST-elevation myocardial infarction 
(STEMI), there is still some concern about the long-term safety 
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of drug-eluting stents (DES). In the SCAAR registry, over 6 
years (2007-2013), 34,147 patients with STEMI were treated 
by primary percutaneous coronary intervention (PCI) with 
new generation DES (n-DES) (n=4,811), old-generation DES 
(o-DES) (n=4,271), or bare metal stents (BMS) (n=25,065). 
There was a significantly lower risk of early/late stent throm-
bosis (ST) in patients treated with n-DES (hazard ratio -HR: 
0.65; p=0.04) and o-DES (HR: 0.60; p= 0.01) compared with 
the BMS group. The risk of very late ST was similar between 
the n-DES and BMS groups (HR: 1.52; p=NS), whereas a 
higher risk of very late ST was observed with o-DES compared 
with BMS (HR: 2.88; p<0.01). The authors concluded that 
patients treated with n-DES have a lower risk of early/late ST 
than patients treated with BMS. The risk of very late ST is low 
with n-DES and BMS up to 3 years, but o-DES are associated 
with an increased risk of very late ST (Sarno G et al, J Am Coll 
Cardiol 2014;64:16–24).
Alcohol Consumption, Even at Moderate Intakes,  
is a Risk Factor for Atrial Fibrillation (AF)
The association between alcohol consumption and AF risk 
was investigated by following 79,019 men and women who, at 
baseline, were free from AF. At follow-up (1998 to 2009), 7,245 
incident AF cases were identified. The association between 
alcohol consumption and AF did not differ by gender. Com-
pared with drinkers of <1 drink/ week (12 g alcohol/drink), 
the multivariable relative risks (RRs) of AF were 1.01 for 1-6 
drinks/week, 1.07 for 7-14 drinks/week, 1.14 for 15-21 drinks/
week, and 1.39 for >21 drinks/week. Results did not change 
after excluding binge drinkers. In meta-analysis of 7 prospective 
studies, among 12,554 AF cases, RRs were 1.08 for 1 drink/day, 
1.17 for 2 drinks/day, 1.26 for 3 drinks/day, 1.36 for 4 drinks/
day, and 1.47 for 5 drinks/ day, compared with nondrinkers. 
Thus, alcohol, even at moderate intakes, is a risk factor for AF 
(Larsson et al, J Am Coll Cardiol 2014;64:281-289).
TREAT-AF: In Patients With Recently Identified AF, 
Digoxin is Associated With Increased Risk of Death
According to data of the TREAT-AF study, among 122,465 
male patients (aged 72+10 years) with newly diagnosed, 
nonvalvular atrial fibrillation (AF), 28,679 (23.4%) received 
digoxin. Mortality rates were higher for those who received 
digoxin vs those who did not (95 vs 67 per 1,000 person-years; 
p<0.001). Digoxin use was independently associated with mor-
tality (hazard ratio -HR: 1.26, p<0.001). The risk of death was 
not modified by age, gender, heart failure, kidney function, or 
concomitant beta-blocker, amiodarone, or warfarin use. The 
authors concluded that digoxin was associated with increased 
risk of death in patients with newly diagnosed AF, independent 
of drug adherence, kidney function, cardiovascular comor-
bidities, and concomitant therapies. These findings challenge 
current recommendations on use of digoxin in AF (Turakhia 
MP et al, J Am Coll Cardiol 2014;64:660-668).
Blood Transfusions Conferring Higher  
In-Hospital Mortality in Acute Myocardial  
Infarction (AMI) Patients May Merely Reflect  
a Higher Risk Profile
Among 34,937 AMI hospitalizations, a total of 1,778 pa-
tients (5.1%) had at least 1 blood transfusion. In unadjusted 
analyses, transfusion conferred higher in-hospital mortality 
(odds ratio: 2.05). The majority of patients (91.1%) with and 
without transfusion had non-overlapping propensity scores, 
reflecting incomparable clinical profiles. After propensity 
matching those with overlapping scores, blood transfusion 
was associated with a reduced risk of in-hospital death (odds 
ratio: 0.73). The authors concluded that the majority of AMI 
patients receiving blood transfusion cannot be matched with 
non-transfused patients due to their different clinical profiles. 
Among comparable patients, blood transfusion was associated 
with a lower risk of in-hospital mortality (Salisbury AC et al, 
J Am Coll Cardiol 2014;64:811-819).
European Experience: Percutaneous Transcatheter 
Mitral Valve repair (TMVR) Efficacious  
in Reducing Severity of Primary Mitral  
Regurgitation (MR) With a Relatively Low 
Complication Rate
A total of 628 patients (aged 74 ± 10 years, 63% men) 
with mainly (72%) functional mitral regurgitation (FMR) 
(NYHA class >III; logistic EuroScore 20+17) underwent 
TMVR between 1/2011 and 12/2012 in 25 centers in 8 Euro-
pean countries. Acute success was high (95.4%) with one clip 
implanted in 61.4% of patients. In-hospital mortality was low 
(2.9%). The estimated 1-year mortality was 15.3%, which was 
similar for FMR and degenerative MR. The estimated 1-year 
rate of rehospitalization because of heart failure was 22.8%, 
significantly higher in the FMR group (25.8% vs 12.0%, 
p=0.009). Paired echocardio-graphic data (n=368) showed 
a persistent reduction in the degree of MR at 1 year (6% of 
patients with severe MR). The authors concluded that TMVR 
is associated with high immediate success, low complication 
rates, and sustained 1-year reduction of the severity of MR 
and improvement of clinical symptoms (Nickenig G et al, J 
Am Coll Cardiol 2014;64:875-884).
MADIT-CRT: A Percentage as Low as ≥0.1% of Ectopic 
Beats Leads to <97% Biventricular Paced Beats and 
Higher Risk of Non-Response to CRT
From the MADIT-CRT, 801 patients with an implanted 
CRT-defibrillator device had data available on biventricular 
pacing percentage and pre-implantation 24-h Holter record-
ings. Ectopic beats accounted for a mean 3.2 ± 5.5% of all 
beats. The probability of subsequent low biventricular pacing 
percentage (<97%) was increased 3-fold (odds ratio: 3.37; p 
<0.001) in patients with 0.1%-1.5% ectopic beats and 13-fold 
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(odds ratio: 13.42; p<0.001) in patients with >1.5% ectopic 
beats compared with those with <0.1% ectopic beats. Patients 
with ≥0.1% ectopic beats had significantly less reverse remod-
eling (p<0.001). The risk of heart failure/death and ventricular 
tachyarrhythmias was increased significantly in those with 0.1% 
- 1.5% ectopic beats (hazard ratio: 3.13 and 1.84, respectively) 
and for >1.5% ectopic beats (hazard ratio: 2.38 and 2.74, re-
spectively). The authors concluded that a small percentage of 
ectopic beats (≥0.1%) dramatically increases the probability of 
low biventricular pacing (<97%), with reduced CRT efficacy 
(Ruwald MH et al, J Am Coll Cardiol 2014;64:971-981).
Nadolol Appears to be the Preferred β-Blocker in 
the General Management of Patients With Long QT 
Syndrome (LQTS)
Among 1,530 LQTS patients receiving β-blockers, relative 
to being off β-blockers, the hazard ratio for first cardiac events 
was 0.71 for atenolol, 0.70 for metoprolol, 0.65 for propranolol, 
and 0.51 for nadolol. In LQT1, the risk reduction for first car-
diac events was similar among the 4 β-blockers, but in LQT2, 
nadolol provided the only significant risk reduction (hazard 
ratio: 0.40). Among patients who had a prior cardiac event 
while taking β-blockers, efficacy for recurrent events differed 
by drug (p=0.004), and propranolol was the least effective. 
The authors concluded that although the 4 β-blockers are 
equally effective in reducing the risk of a first cardiac event 
in LQTS, their efficacy differed by genotype; nadolol was the 
only β-blocker associated with a significant risk reduction 
in patients with LQT2. Patients experiencing cardiac events 
while on β-blocker therapy are at high risk for subsequent 
cardiac events, and propranolol is the least effective drug in 
this high-risk group (Abu-Zeitone A et al, J Am Coll Cardiol 
2014;64:1352-1358).
ADVANCE III Trial: Programming a Long Detection 
Window Setting in ICDs Leads to a Reduction of 
Electrical Therapies and Shocks Even in the Subgroup 
of Secondary Prevention Patients
Of the 1902 patients enrolled in the ADVANCE III trial, 
477 received a defibrillator (ICD) for secondary prevention; 
248 patients were randomly assigned to a long detection set-
ting (30/40 intervals) and 229 to the nominal setting (18/24 
intervals) for ventricular arrhythmias with cycle length ≤320 
ms (188 bpm). Over a median period of 12 months, the long 
detection period conferred a 25% reduction in the number of 
overall therapies and a 34% reduction in the number of ICD 
shocks. Appropriate therapies and appropriate shocks were also 
reduced. The authors concluded that a long detection window 
setting in ICDs leads to a reduction of electrical therapies in 
both primary and secondary prevention populations (Kloppe 
A et al, Circulation 2014;130:4 308-314).
Bilateral Internal Mammary Artery Grafts Improve 
Long-Term Survival
In a meta-analytic approach (9 observational studies, 15,583 
patients), long-term (10-year) survival was compared between 
bilateral (BIMA, n=7313) and single internal mammary artery 
(SIMA, n=8270) grafting. Use of BIMA conferred a signifi-
cant reduction in mortality (hazard ratio, 0.79). The authors 
concluded that BIMA grafting appears to have better survival 
with up to 10 years follow-up in comparison with SIMA graft-
ing (Yi G et al, Circulation 2014;130:7 539-545).
Registry Study of 2169 Patients Indicates that Catheter 
Ablation Improves Long-term Outcome in Wolff-
Parkinson-White (WPW) Syndrome
Among 2169 patients with WPW syndrome, 1168 (206 
asymptomatic) underwent ablation (RFA group) and 1001 (550 
asymptomatic) did not (no-RFA group). Over 8 years, in the 
no-RFA group, VF occurred in 1.5% of patients, mostly (13 
of 15) in children (median age, 11 years), and was associated 
with a short accessory pathway antegrade refractory period 
(P<0.001) and atrioventricular reentrant tachycardia degener-
ating into atrial fibrillation (P<0.001) but not with symptoms. 
In the RFA group, ablation was successful in 98.5%, and after 
RFA, no patients developed malignant arrhythmias or VF. 
An anterograde effective refractory period of the accessory 
pathway of <240 ms predicted VF. The authors concluded 
that the prognosis of the WPW syndrome depends on elec-
trophysiological properties of AP rather than on symptoms, 
and RFA improves the long-term outcomes (Pappone C et al, 
Circulation 2014;130:10 811-819).
Hybrid Coronary Revascularization is Performed in 
1/3 of US Hospitals and May be a Safe Alternative for 
CABG
Hybrid (combined surgical and percutaneous) coro-
nary revascularization (HCR) represented 0.48% (n=950; 
staged=809, concurrent=141) of the total CABG volume 
(n=198 622) during the period from July 2011 to March 
2013, and was performed in 1/3 of hospitals (n=361) in the 
US. Patients who underwent HCR had higher cardiovascular 
risk profiles. In comparison with CABG, median sternotomy 
direct vision harvesting and cardiopulmonary bypass were 
less frequently used for staged and concurrent HCR, whereas 
robotic assistance was more common. No differences were 
observed for in-hospital mortality and major morbidity. There 
was no significant association between operative mortality and 
either treatment group. HCR, either as a staged or concurrent 
procedure, is performed in 1/3 of US hospitals, and may be 
an equally safe alternative for CABG (Harskamp RE et al, 
Circulation 2014;130:11 872-879).
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Rate and Predictors if ICD Infection in a Large Cohort 
of Medicare Patients: Avoid Re-Intervention Except for 
Battery Replacement
Between 2006 and 2009 of 200,909 ICD implants, 3390 
patients (1.7%) developed a device infection. Infection rate 
was 1.4%, 1.5%, and 2.0% for single, dual, and biventricular 
ICDs, respectively (P<0.001). Pulse generator replacement 
had a higher rate compared with initial implant (1.9% vs 1.6%, 
P<0.001). The factors associated with infection were adverse 
re-intervention (odds ratio -OR, 2.7), prior valve surgery 
(OR, 1.5), re-implantation for device upgrade, malfunction, 
or manufacturer advisory (OR, 1.35), renal failure on dialysis 
(OR, 1.34), chronic lung disease (OR, 1.21), cerebrovascular 
disease (OR, 1.17), and warfarin (OR, 1.15). The authors con-
cluded that patients who developed an ICD infection were more 
likely to have had peri-ICD implant complications requiring 
early re-intervention, previous valve surgery, device replace-
ment for reasons other than battery depletion, and increased 
comorbidity burden. Their advice is to avoid reentering the 
pocket at any time other than battery change (Prutkin JM et 
al, Circulation 2014;130:1037-1043).
STREAM 1-Year Follow-Up: A Dose-Adjusted 
Pharmaco-invasive Strategy is as Good as Primary PCI 
When Timely Primary PCI is Unattainable in STEMI
In the STREAM trial, a pharmaco-invasive (PI) strategy 
was compared with primary percutaneous coronary interven-
tion (pPCI) in STEMI patients presenting within 3 hours after 
symptom onset but unable to undergo pPCI within 1 hour. The 
PI approach included tenecteplase coupled with antiplatelet and 
anticoagulant therapy followed by coronary angiography within 
6 - 24 hours. From 2009 onward the dose of tenecteplase was 
reduced by 50% in patients aged ≥75 years to reduce intracranial 
bleed. For failed thrombolysis, rescue PCI was performed. At 
30 days, the PI approach was associated with nonstatistically 
lower incidence of the composite primary end point of death, 
shock, congestive heart failure, and reinfarction when compared 
with pPCI. At 1 year, all-cause mortality (6.7% vs 5.9%) and 
cardiac mortality rates (4.0% vs 4.1%) were similar for PI and 
pPCI-treated patients. Overall, only 34 patients died between 
day 30 and 1 year, 20 in the PI arm and 14 in the pPCI arm, of 
whom 20 died of noncardiac reasons (13 in the PI and 7 in the 
pPCI arm). The authors concluded that at 1 year, mortality 
rates in the PI and pPCI arms were similar in STEMI patients 
presenting within 3 hours after symptom onset and unable to 
undergo pPCI within 1 hour (Sinnaeve PR et al, Circulation 
2014;130:1139-1145).
EFFORTLESS S-ICD Registry: Appropriate 
Performance for the Subcutaneous ICD With Event 
Rates and Inappropriate Shock Rates Comparable 
With Those of Conventional ICDs
The totally subcutaneous implantable-defibrillator (S-ICD) is 
a new alternative to the conventional transvenous ICD system to 
minimize intravascular lead complications. The EFFORTLESS 
S-ICD Registry included 472 patients (72% male, aged 49+18 
years; mean left ventricular ejection fraction 42%). Complication-
free rates were 97% at 1 month and 94% at 1 year. There were 
recorded 317 spontaneous episodes in 85 patients during the 
1.5-year mean follow-up period; of these, 169 (53%) received 
therapy, 93 being for ventricular tachycardia/fibrillation (VT/
VF). One patient died of recurrent VF and severe bradycardia. 
First shock conversion efficacy was 88% with 100% successful 
clinical conversion after a maximum of 5 shocks. The 1-year 
inappropriate shock rate was 7% with the majority occurring 
for oversensing (62/73 episodes), primarily (94%) of cardiac 
signals. The authors concluded that the S-ICD has appropriate 
performance with clinical event rates and inappropriate shock 
rates comparable with those reported for conventional ICDs 
(Lambiase PD et al, Eur Heart J 2014; 35:1657–1665).
Dresden NOAC Registry: Peri-Interventional Short-
Term Interruption of Novel Anticoagulants (NOACs) 
is Safe / Bleeding Complications are Related to Major 
Procedures or to Peri-Procedural Heparin Bridging
Of 2179 patients receiving NOACs, 595 (27.3%) underwent 
863 interventional procedures (15.6% minimal, 74.3% minor, 
and 10.1% major procedures). Until 1 month post-procedure, 
major cardiovascular events occurred in 1% and major bleeding 
complications in 1.2%. Cardiovascular (4.6%) and major bleed-
ing complications (8%) were highest after major procedures. 
Heparin bridging did not reduce cardiovascular events, but led 
to higher rates of major bleeding (2.7% vs 0.5% with no bridg-
ing). Diabetes (odds ratio -OR 13.2) and major procedures (OR 
7.3) were independent risk factors for cardiovascular events. 
Major procedures (OR 16.8) were an independent risk factor 
for major bleeding. The authors concluded that continuation 
or short-term interruption of NOAC is safe for most invasive 
procedures. Patients undergoing major procedures may ben-
efit from heparin bridging, but at the expense of bleeding risk 
(Beyer-Westendorf J et al, Eur Heart J 2014; 35:1888–1896).
CENTURY II Trial: The New Sirolimus-Eluting Co-Cr 
Stent With Bioresorbable Polymer (Ultimaster BP-
SES) is Safe and Effective as Everolimus-Eluting Co-
Cr Stent With Permanent Polymer (Xience PP-EES)
The new sirolimus-eluting stent with bioresorbable polymer, 
Ultimaster (BP-SES), was compared with everolimus-eluting, 
permanent polymer, Xience stent (PP-EES) in 1123 patients 
undergoing percutaneous coronary intervention (PCI). The 
primary endpoint, freedom from target lesion failure (TLF) 
at 9 months (cardiac death, target-vessel-related myocardial 
infarction and target lesion revascularization) was 95.6% with 
BP-SES and 95.1% with PP-EES. Composite of cardiac death 
and MI rate was 2.9 and 3.8% (P = NS) and target vessel revas-
cularization was 4.5% with BP-SES and 4.2% with PP-EES 
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(P=NS). The stent thrombosis rate was 0.9% in both arms. 
The authors concluded that the new bioresorbable polymer 
sirolimus-eluting stent had similar safety and efficacy to durable 
polymer everolimus-eluting stent over 9 months (Saiot S et al, 
Eur Heart J 2014; 35:2021–2031).
Favorable Long-Term Survival After Alcohol Septal 
Ablation for Hypertrophic Obstructive Cardiomyopathy
A total of 178 highly symptomatic (87% with dyspnea >3 
class NYHA) patients with hypertrophic obstructive cardio-
myopathy (HOCM) (58 ± 12 years, 53% women) were treated 
by alcohol septal ablation (ASA) (1998-2013). At the most 
recent examination, 87 patients (49%) had dyspnea NYHA 
class I and 23 patients (13%) reported dyspnea of NYHA 
class ≥3. The left ventricular outflow gradient was significantly 
reduced (68 ± 42 vs. 20 ± 25 mmHg; P<0.01). A total of 19 
deaths (11%) occurred over 4.8 years (2.1% per year). Survival 
free of all-cause mortality at 1, 5, and 10 years was 97%, 92%, 
and 82%, respectively, which was comparable to the expected 
survival for age- and sex-comparable general population. The 
only independent predictor of all-cause mortality was age at 
ASA (hazard ratio 1.09; P<0.01). The authors concluded that 
in symptomatic patients with HOCM undergoing ASA, long-
term survival did not differ from that of the general population 
(Veselka J et al, Eur Heart J 2014;35:2040-2045).
PROFICIO: Large and Rapid Reductions Achievable in 
Apo B and Its Related Lipoproteins, LDL-C, VLDL-C, 
and Non-HDL-C With Evolocumab
A pooled analysis of 1359 patients from 4 phase-2 studies 
of evolocumab, a monoclonal antibody to PCSK9, showed 
mean percentage reductions in LDL-C vs placebo ranging 
from 40.2% to 59.3% among the evolocumab groups (all 
P<0.001). Significant reductions in apo-lipoprotein B (Apo 
B), non-high-density lipoprotein cholesterol (non-HDL-C), 
triglycerides and lipoprotein (a) - Lp(a), and increases in 
HDL-C were also observed. Adverse events (AEs) and seri-
ous AEs with evolocumab were reported in 56.8 and 2.0% 
of patients, compared with 49.2% and 1.2% with placebo. 
Cardiac and cerebrovascular events were reported in 0.3 and 
0% in the placebo and 0.9 and 0.3% in the evolocumab arms, 
respectively. The authors concluded that in addition to LDL-C 
reduction, evolocumab, dosed either every 2 weeks or every 
4 weeks, demonstrated significant and favourable changes in 
other atherogenic and anti-atherogenic lipoproteins, and was 
well tolerated over the 12-week treatment period (Stein EA 
et al, Eur Heart J 2014; 35: 2249–2259).
REMINDER Study: Compared With Placebo, Addition 
of Eplerenone to Standard Therapy Within 24 h of 
Symptom Onset is Safe and Reduces BNP Levels of 
Patients Presenting With STEMI Without Known HF 
or LVEF<40%
A total of 1012 patients with STEMI and without a history 
of heart failure (HF) were assigned to receive either eplerenone 
(25–50 mg qd) or placebo in addition to standard therapy. 
The primary endpoint was the composite of CV mortality, 
re-hospitalization, or, extended initial hospital stay, due to 
diagnosis of HF, sustained ventricular tachycardia or fibrilla-
tion, ejection fraction ≤40%, or elevated BNP (>200 pg/mL)/ 
NT-proBNP (>450 pg/mL, age <50; >900 pg/mL, age 50-75; 
>1800 pg/mL age >75 years) at 1 month or more after rand-
omization. Over a mean of 10.5 months, the primary endpoint 
occurred in 92 patients (18.2%) in the eplerenone group and 
in 149 patients (29.4%) in the placebo group (hazard ratio - 
HR, 0.58; P <0.0001]. Adverse event rates were similar in both 
groups. Serum potassium levels exceeded 5.5 mmol/L in 5.6 vs 
3.2% (P = 0.09) and were below 3.5 mmol/L in 1.4 vs 5.6% of 
patients (P = 0.0002), in the eplerenone and placebo groups, 
respectively. The authors concluded that adding eplerenone 
during the acute phase of STEMI is safe and well tolerated. It 
reduced the primary endpoint over a mean 13 months follow-
up mostly because of significantly lower BNP/NT-proBNP 
levels (Montalescot G et al, Eur Heart J 2014; 35:2295–2302).
PURE Studies: A Questionable Method of Estimated 
Sodium Excretion (from a Morning Urine Sample), 
Used as a Surrogate for Sodium Intake, Showed a 
Nonlinear Association of Sodium With Blood Pressure, 
Most Pronounced Among Persons Consuming High-
Sodium Diets, Hypertensive and Older Persons / The 
Lowest Risk of Death and Cardiovascular Events was 
Seen at Sodium Excretion of 3-6 g/d. Both Higher and 
Lower Levels of Sodium Excretion Were Associated 
With Increased Risk (a J-Shaped Association Curve)
A total of 102,216 adults from 18 countries were studied. 
Estimates of 24-hour sodium and potassium excretion were 
made from a single fasting morning urine specimen and were 
used as surrogates for intake. Analysis showed increments 
of 2.11 mm Hg in systolic blood pressure and 0.78 mm Hg in 
diastolic blood pressure for each 1-g increment in estimated 
sodium excretion. The slope of this association was steeper with 
higher sodium intake and for hypertensive or older persons. 
Potassium excretion was inversely associated with systolic 
blood pressure. The authors concluded that the association of 
estimated intake of sodium and potassium with blood pressure 
was nonlinear and was most pronounced in persons consuming 
high-sodium diets, and hypertensive and older persons (Mente 
A et al, N Engl J Med 2014; 371:601-611).
In the second part of the study, over a mean follow-up 
of 3.7 years, the composite outcome of deaths and major 
cardiovascular events occurred in 3317 participants (3.3%). 
As compared with an estimated sodium excretion of 4-6 g/d, a 
higher estimated sodium excretion (≥7 g/d) was associated with 
an increased risk of the composite outcome (odds ratio, 1.15), 
with strongest association among hypertensive participants with 
an increased risk at an estimated sodium excretion of >6 g/d. 
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An estimated sodium excretion <3 g/d was also associated with 
an increased risk of the composite outcome (odds ratio, 1.27). 
Higher potassium excretion was associated with a reduced risk 
of the composite outcome. The authors concluded that sodium 
intake estimated on the basis of measured urinary excretion, 
between 3-6 g/d was associated with a lower risk of death and 
cardiovascular events than was either a higher or lower level 
of intake. Higher potassium excretion was associated with a 
lower risk of death and cardiovascular events (O’Donnell M 
et al, N Engl J Med 2014; 371:612-623). (The main critique to 
both these studies relates to the estimated sodium intake based 
on a morning fasting midstream urine sample rather than on 
24-hour urine collection).
NUTRICODE Study: in 2010, a Total of 1.65 Million 
Cardiovascular Deaths Were Attributable to Sodium 
Consumption of >2 g/d (or Salt > 5 g/d)
Data from surveys on sodium intake, as determined by 
urinary excretion and diet in persons from 66 countries, were 
used to quantify the global consumption of sodium according 
to age, gender, and country. The effects of sodium on blood 
pressure were calculated from data in a meta-analysis of 107 
randomized interventions, and the effects of blood pressure 
on cardiovascular mortality, according to age, were calculated 
from a meta-analysis of cohorts. In 2010, the estimated mean 
level of global sodium consumption was 3.95 g/d. Globally, 
1.65 million annual deaths from cardiovascular causes were 
attributed to sodium intake above the reference level of >2 
g/d (62% in men and 38% in women). These deaths accounted 
for nearly 1 of every 10 deaths from cardiovascular causes 
(9.5%). Four of every 5 deaths (84.3%) occurred in low- and 
middle-income countries, and 2 of every 5 deaths (40.4%) 
were premature (< age of 70 years), with highest death rate 
in the country of Georgia and lowest in Kenya. The authors 
concluded that 1.65 million deaths from cardiovascular causes 
that occurred in 2010 were attributed to sodium consumption 
above a reference level of 2.0 g/d (> 5 g of salt per day) (Mo-
zaffarian D et al, N Engl J Med 2014; 371:624-634).
PARADIGM-HF: Angiotensin Receptor–Neprilysin 
Inhibition With Valsartan/Sucabitril (LCZ696) is 
Superior to ACE Inhibition Alone in Reducing Risks of 
Death and Hospitalization for Heart Failure / Strong 
Evidence that Combined Inhibition of the Angiotensin 
Receptor and Neprilysin is Superior to Inhibition of 
the Renin–Angiotensin System Alone in Patients With 
Chronic Heart Failure
A total of 8442 patients with class II-IV heart failure and an 
ejection fraction of <40% were randomly assigned to receive 
either valsartan/sucabitril (LCZ696) (200 mg bid) or enalapril 
(10 mg bid), in addition to recommended therapy. The trial was 
stopped early at a median follow-up of 27 months. The primary 
outcome (composite of death from cardiovascular causes or 
hospitalization for heart failure) had occurred in 914 patients 
(21.8%) in the LCZ696 group and 1117 patients (26.5%) in 
the enalapril group (hazard ratio-HR 0.80; P<0.001); mortality 
was 17% vs 19.8% (HR, 0.84; P<0.001), and cardiovascular 
mortality 13.3% vs 16.5% (HR, 0.80; P<0.001), respectively. 
The new drug decreased the risk of hospitalization for heart 
failure by 21% (P<0.001). The new drug caused higher rates 
of hypotension and nonserious angioedema but lower rates 
of renal impairment, hyperkalemia, and cough than enalapril. 
The authors concluded that LCZ696 was superior to enalapril 
in reducing the risks of death and of hospitalization for heart 
failure (McMurray JJV et al, N Engl J Med 2014; 371:993-1004).
ATLANTIC study: Prehospital Ticagrelor in STEMI is 
not Necessary
A total of 1862 patients with STEMI of <6 hours’ duration 
received ticagrelor as prehospital (in the ambulance) or in-
hospital (in the catheterization laboratory) treatment (median 
time from randomization to angiography: 48 min; median time 
difference between the two treatment strategies: 31 min). The 
two coprimary end points (proportion of patients who did not 
have a >70% resolution of ST elevation before PCI and those 
who did not have TIMI flow grade 3 in the infarct-related artery 
at initial angiography) did not differ between the 2 groups. 
The absence of ST-elevation resolution of >70% after PCI 
(secondary end point) was reported for 42.5% and 47.5% of 
patients, respectively. Rates of major adverse cardiovascular 
events did not differ between the 2 groups. Rates of definite 
stent thrombosis were lower in the prehospital group (0% vs 
0.8% in the first 24 hours; 0.2% vs 1.2% at 30 days). Rates 
of major bleeding were low and similar in the 2 groups. The 
authors concluded that prehospital administration of ticagrelor 
in patients with STEMI was safe but did not improve pre-PCI 
coronary reperfusion (Montalescot G et al, N Engl J Med 2014; 
371:1016-1027).
SIGNIFY: No Benefit of Ivabradine in Patients With 
Stable Coronary Artery Disease Without Clinical 
Heart Failure
A total of 19,102 patients with stable coronary artery 
disease (CAD) and heart rate >70 bpm without heart failure 
were randomized to ivabradine (10 mg bid) to achieve a heart 
rate of 55 - 60 bpm. At 3 months, heart rate was 60.7±9 bpm 
in the ivabradine group vs 70.6±10.1 bpm in the placebo 
group. After a median follow-up of 27.8 months, there was 
no significant difference between the 2 groups in the primary 
end point (composite of death from cardiovascular causes or 
nonfatal myocardial infarction) (6.8% and 6.4%, respectively; 
hazard ratio, 1.08; P=NS). The incidence of bradycardia was 
higher with ivabradine (18% vs 2.3%, P<0.001). The authors 
concluded that in patients with stable CAD without clinical 
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heart failure, the addition of ivabradine to standard therapy 
to reduce the heart rate did not improve outcomes (Fox K et 
al, N Engl J Med 2014; 371:1091-1099).
TASTE at 1 Year: No Benefit of Thrombus Aspiration 
for Myocardial Infarction (MI)
A total of 7244 patients with STEMI were randomly as-
signed to undergo manual thrombus aspiration followed by 
PCI or PCI alone, in a registry-based, randomized clinical 
trial. Mortality at 1 year was 5.3% in the thrombus-aspiration 
group vs 5.6% in the PCI-only group (hazard ratio-HR, 0.94; 
P=NS). Re-hospitalization for MI at 1 year occurred in 2.7% 
and 2.7% of the patients (HR, 0.97; P=NS), and stent throm-
bosis in 0.7% and 0.9%, respectively (HR, 0.84; P=NS). The 
composite of death from any cause, rehospitalization for MI, 
or stent thrombosis occurred in 8.0% and 8.5% of patients, 
respectively (HR, 0.94; P=NS). The authors concluded that 
routine thrombus aspiration before PCI in patients with STEMI 
did not reduce the rate of death from any cause or the compos-
ite of death from any cause, rehospitalization for myocardial 
infarction, or stent thrombosis at 1 year (Lagerqvist B et al, N 
Engl J Med 2014; 371:1111-1120).
FAME 2: Favorable Results From Fractional Flow 
Reserve–Guided PCI in Stable Coronary Disease
In 1220 patients with stable coronary artery disease, frac-
tional flow reserve (FFR) was assessed in all coronary stenoses. 
Patients with >1 stenosis with an FFR of <0.80 were randomly 
assigned to undergo FFR-guided PCI plus medical therapy or 
to receive medical therapy alone. Patient with all stenoses hav-
ing FFR >0.80 received medical therapy alone (included in a 
registry). The primary end point (composite of death from any 
cause, nonfatal MI, or urgent revascularization within 2 years) 
was significantly lower in the PCI group (8.1% vs 19.5%; hazard 
ratio-HR, 0.39; P <0.001), driven by a lower rate of urgent 
revascularization (4.0% vs 16.3%; HR, 0.23; P <0.001); there 
were no between-group differences in rates of death and MI. 
Urgent revascularizations were less frequent in the PCI group 
(3.4% vs 7.0%, P=0.01). Rate of death or MI from 8 days to 
2 years was lower in the PCI group (4.6% vs 8.0%, P=0.04). 
In the registry patients, the rate of the primary end point was 
9.0% at 2 years. The authors concluded that in patients with 
stable coronary artery disease, FFR-guided PCI improved 
the outcome. Patients without ischemia (normal FFR) had a 
favorable outcome with medical therapy alone (De Bruyne B 
et al, N Engl J Med 2014; 371:1208-1217).
ARIC: an Elevated (≥140 mmHg) Systolic BP Carries 
the Highest Risk for Cardiovascular Events / BP <120 
Confers no Additional Benefit Compared With BP<140
Among 4480 individuals with hypertension (HTN) but with-
out prevalent cardiovascular (CV) disease at baseline, a total of 
1622 incident CV events (heart failure, ischemic stroke, myo-
cardial infarction, or death related to coronary heart disease) 
occurred over a median follow-up of ~22 years. Elevated (>140 
mmHg) systolic blood pressure (SBP) conferred significantly 
more CV events than low BP (<120 mmHg) (hazard ratio 
-HR, 1.46), with no difference noted in the standard (120-140 
mmHg) vs low SBP group (HR, 1.00). No effect related to 
BP medication use or diastolic BP was observed. The authors 
concluded that among patients with HTN, an elevated SBP 
carries the highest risk for CV events, but once SBP was <140 
mmHg, an SBP <120 mmHg did not appear to lessen the risk 
(Rodriguez CJ, JAMA Intern Med 2014;174:1252-1261).
83% 1-Year Survival after Transcatheter Valve-in-Valve 
Implantation
A multinational registry included 459 patients with degen-
erated bioprosthetic valves undergoing valve-in-valve implan-
tation (2007 – 2013) with both balloon- and self-expandable 
valves. Within 1 month, 35 (7.6%) patients died, 8 (1.7%) had 
major stroke, and 313 (92.6%) of surviving patients had good 
functional status (New York Heart Association class I/II). 
Overall 1-year survival rate was 83.2% (62 death events; 228 
survivors). Patients in the stenosis group had worse survival 
(76.6%) in comparison with the regurgitation (91.2%) and the 
combined group (83.9%) (P = 0.01). Patients with small valves 
had worse 1-year survival (74.8%) vs with intermediate-sized 
valves (81.8%) and with large valves (93.3%) (P = .001). Fac-
tors associated with 1-year mortality included small surgical 
bioprosthesis (≤21 mm; hazard ratio, 2.04; P = .02) and baseline 
stenosis (vs regurgitation; hazard ratio, 3.07; P = .008). The 
authors concluded that in this registry of patients who under-
went transcatheter valve-in-valve implantation for degenerated 
bioprosthetic aortic valves, overall 1-year survival was 83%. 
Survival was lower among patients with small bioprostheses 
and those with predominant surgical valve stenosis (Dvir D 
et al, JAMA 2014;312:162-170).
Perioperative Atrial Fibrillation (AF) Confers High 
Long-term Risk of Ischemic Stroke
In a retrospective study (2007-2011) of 1,729,360 patients 
hospitalized for surgery, 24,711 (1.43%) had new-onset perio-
perative AF and 13,952 (0.81%) had a stroke after discharge. 
At 1 year after cardiac surgery, stroke rate was 0.99% in 
those with perioperative AF and 0.83% in those without AF. 
At 1 year after noncardiac surgery, stroke rate was 1.47% in 
those with perioperative AF and 0.36% in those without AF. 
Perioperative AF was associated with subsequent stroke both 
after cardiac (hazard ratio-HR, 1.3) and noncardiac surgery 
(HR, 2.0). The authors concluded that among patients having 
surgery, perioperative AF conferred an increased long-term 
risk of ischemic stroke, especially after noncardiac surgery 
(Gialdini G et al, JAMA 2014;312:616-622).
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SOLID-TIMI 52: No Benefit of Darapladib on Major 
Coronary Events After an Acute Coronary Syndrome
A total of 13 026 patients were randomized (2009-2013) 
within 30 days of an acute coronary syndrome (ACS) to either 
once-daily darapladib (160 mg) (an oral, selective inhibitor 
of lipoprotein-associated phospholipase A2 - Lp-PLA2) or 
placebo. During a median of 2.5 years, major coronary events 
occurred in 903 patients in the darapladib group and 910 in the 
placebo group (16.3% vs 15.6% at 3 years; hazard ratio - HR, 
1.00; P = NS). There was no difference between the treatment 
groups in all-cause mortality (7.3% vs 7.1% at 3 years; HR, 
0.94; P = NS). Darapladib caused more diarrhea and an odor-
related concern. The authors concluded that in patients with 
ACS, direct inhibition of Lp-PLA2 with darapladib added to 
optimal medical therapy and initiated within 30 days of hos-
pitalization did not reduce the risk of major coronary events 
(O’Donoghue ML et al, JAMA 2014;312:1006-1015).
Meta-Analysis: Bivalirudin Increases MACE 
Compared With Heparin in Patients Planned for 
Percutaneous Coronary Intervention (PCI)
Data from 16 trials involving 33,958 patients indicated an 
increase in the risk of major adverse cardiac events (MACE) 
with bivalirudin-based regimens compared with heparin-based 
regimens (risk ratio-RR 1.09; p=0·0204), largely driven by 
increases in myocardial infarction (MI) (RR 1.12) and ischemia-
driven revascularisation (RR 1.16), with no effect on mortality 
(RR 0.99). Bivalirudin increased the risk of stent thrombosis 
(RR 1.38; p=0.0074), primarily due to an increase in acute cases 
of MI (RR 4.27; p<0·0001). Overall, bivalirudin-based regimens 
lowered the risk of major bleeding (RR 0.62; p<0·0001), but 
the magnitude of this effect varied (p<0·0001) depending on 
whether glycoprotein IIb/IIIa inhibitors were used. The authors 
concluded that compared with a heparin-based regimen, a 
bivalirudin-based regimen increases the risk of MI and stent 
thrombosis, but decreases the risk of bleeding (Cavender MA 
& Sabatine MS, Lancet 2014; 384 (9943): 599 – 606).
Important Review and Other Articles
Renal denervation for treatment of cardiac arrhythmias 
(Kosiuk J et al, J Cardiovasc Electrophysiol 2014 Sep 18. doi: 
10.1111/jce.12553. [Epub ahead of print], 2014 AHA/ ACC 
Guideline for the management of patients with NSTE ACS 
(Amsterdam EA et al, J Am Coll Cardiol 2014; doi: 10.1016/j.
jacc.2014.09.017), The MOGE(S) classification of cardio-
myopathy (J Am Coll Cardiol 2014;64:304-318), Hypertrophic 
cardiomyopathy (Baron et al, J Am Coll Cardiol 2014;64:83-99), 
Aspirin in primary cardiovascular disease prevention (Hal-
vorsen S et al, J Am Coll Cardiol 2014;64:319-327), Rhythm 
control in heart failure patients with AF (Trulock KM et al, 
J Am Coll Cardiol 2014;64:710-721), Carotid artery stenting 
(White CJ, J Am Coll Cardiol 2014;64:722-731), AF ablation 
(Nishida K et al, J Am Coll Cardiol 2014;64:823-831), Fibro-
muscular dysplasia involving coronary arteries (Michelis KC 
et al, J Am Coll Cardiol 2014;64:1033-1046), CRT (Leyva F et 
al, J Am Coll Cardiol 2014;64:1047-1058), ICDs in patients not 
included or not well represented in clinical trials (Kusumoto 
FM et al, J Am Coll Cardiol. 2014;64(11):1143-1177), Triple 
therapy for AF and PCI (Dewilde W et al, J Am Coll Cardiol 
2014;64:1270-1280), Chronic total occlusions (Strauss BH et 
al, J Am Coll Cardiol 2014;64:1281-1289), Superresponse to 
CRT (Steffel J & Ruschitzka F, Circulation 2014;130:1 87-90), 
Left atrial appendage closure in patients with AF (Price MJ 
& Valderrabano M, Circulation 2014;130:2 202-212), Cardio-
vascular management in pregnancy (Brickner ME, Circulation 
2014;130:3 273-282), Chronic venous insufficiency (Eberhardt 
RT & Raffetto JD, Circulation 2014;130:4 333-346), Chronic 
thromboembolic pulmonary hypertension (Lang IM & Madani 
M, Circulation 2014;130:6 508-518), Anderson-Fabry disease 
(Nagueh SF, Circulation 2014;130:13 1081-1090), Risk stratifi-
cation for sudden cardiac death (Wellens HJJ et al, Eur Heart 
J 2014;35: 1642-1651), Edoxaban (Lip G & Agnelli G, Eur 
Heart J 2014;35: 1844-1855), Post-infarct ventricular septal 
rupture (Jones BM et al, Eur Heart J 2014;35: 2060-2068), 
Aortic stenosis and coronary artery disease (Paradis J et al, 
Eur Heart J 2014;35: 2069-2082), Cardiac tamponade (Ristic 
AD et al, Eur Heart J 2014;35: 2279-2284), Catheter ablation 
of AF (Haegeli LM & Calkins H, Eur Heart J 2014;35: 2454-
2459), Aortic stenosis (Otto CM & Prendergast B, N Engl J 
Med 2014; 371:744-756), Screening for abdominal aortic aneu-
rysm (LeFevre ML et al, Ann Intern Med 2014; 161: 281-290), 
Screening for asymptomatic carotid artery stenosis (Jonas DE 
et al, Ann Intern Med 2014;161:336-346; LeFevre ML et al, Ann 
Intern Med 2014;161:356-362).
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Cardiology News / Recent Literature Review / Last 
Quarter 2014
Antonis S. Manolis, MD, Hector Anninos, MD, 
Athens University School of Medicine, Athens, Greece
20th Annual Boston AF Symposium: Orlando, 8-10/1/15
HCS Working Groups Seminar: Ioannina, 2/2015
ACC: San Diego, 14-16/3/15
HRS: Boston, 13-16/5/15
EuroPCR: Paris, 19-22/5/15
Europace: Milan, 21-24/6/15
ESC: London, 29/8-2/9/15
AFFORD study: n-3 Polyunsaturated Fatty Acids (Fish 
Oil) do not Reduce Atrial Fibrillation Recurrences
In a double-blind, randomized, placebo-controlled trial of 
fish oil (4 g/day, docosahexaenoic acid - DHA: eicosapentaenoic 
acid - EPA 1:2) vs safflower oil placebo in 337 patients with 
symptomatic paroxysmal or persistent AF followed for 9 ± 4 
months, the primary endpoint (time to first symptomatic or 
asymptomatic AF recurrence lasting >30 s) occurred in 64% of 
patients in the fish oil arm and 63% of patients in the placebo 
arm (hazard ratio: 1.10; p= NS). hs-CRP and myeloperoxidase 
- MPO were normal at baseline and decreased to a similar 
degree at 6 months. The authors concluded that high-dose fish 
oil does not reduce AF recurrence in patients with a history 
of AF not receiving AA therapy, and does not reduce inflam-
mation or oxidative stress markers in this population (Nigam 
A et al, J Am Coll Cardiol 2014;64:1441-1448).
N.B.: Another randomized study (VITAL - VITamin D 
and OmegA-3 TriaL) is currently examining the effect of 1 g/d 
of n-3 PUFAs on AF in a much larger population (N=25,875) 
without cardiac disease over 5 years.
RELAX-AHF: Serelaxin Reduces Mainly Cardiova-
scular & Sudden Deaths, Rather than HF Deaths
The RELAX-AHF study showed that IV serelaxin (re-
combinant human relaxin-2) compared with placebo reduced 
mortality at 6 months among 1,161 patients with acute heart 
failure (HF). In this group there were 107 deaths (9.3%): 37 
(35%) from HF, 25 (23%) from sudden death, 15 (14%) from 
other cardiovascular (CV) causes, 19 (18%) from non-CV 
causes, and 11 (10%) classified as unknown. The treatment 
effect of serelaxin was most pronounced on other CV deaths 
(hazard ratio - HR: 0.29; p= 0.005) and sudden death (HR: 
0.46; p= 0.065), with no effect of serelaxin treatment on HF 
or non-CV deaths. The authors concluded that the effects of 
serelaxin on mortality were mainly due to reduced CV causes 
and sudden death, without apparent effect on HF deaths 
(Feleker GM et al, J Am Coll Cardiol 2014;64:1591-1598). N.B.: 
an ongoing large phase III outcome trial (NCT01870778) will 
further examine serelaxin’s effect on mortality.
ARISTOTLE: Anticoagulation Quality was Lower in 
Warfarin-Treated Patients who Received Amiodarone, 
and Amiodarone was Associated with Significantly 
Higher Risk of Thrombo-embolism, while Apixaban 
had a Benefit over Warfarin in Both Groups
In the ARISTOTLE trial, 2,051 (11.4%) patients received 
amiodarone. Time in the therapeutic range (TTR) in patients 
on warfarin and amiodarone was lower than patients not on 
amiodarone (56.5% vs 63%; p<0.0001). More patients on 
amiodarone had thromboembolism (stroke or systemic em-
bolism) (1.58%/year vs 1.19%/year; hazard ratio -HR: 1.47; 
p= 0.0322). Mortality and major bleeding rates were higher, 
albeit not significantly different, in the amiodarone vs the 
non-amiodarone group. Apixaban, compared with warfarin, 
decreased systemic embolism, death, and major bleeding in 
both groups. The authors concluded that amiodarone was 
associated with significantly increased stroke and systemic 
embolism risk and a lower TTR when used with warfarin. 
Apixaban consistently reduced the rate of stroke and systemic 
embolism, death, and major bleeding compared with warfarin 
in both (amiodarone and non-amiodarone) groups (Flaker G 
et al, J Am Coll Cardiol 2014;64:1541-1550).
Catheter-Based Transapical Mitral Valve Implanta-
tion was Successful in First 2 Cases with Severe 
Ischemic Cardiomyopathy and Mitral Regurgitation
The first-in-man 2 cases of transapical mitral valve im-
plantation with the Tiara device was successfully performed 
in a 73-year-old man and a 61-year-old woman with severe 
functional mitral regurgitation (MR) and heart failure with 
no need for cardiopulmonary bypass. Systemic arterial pres-
sure and stroke volume increased and pulmonary pressure 
decreased, immediately after the procedure. Both patients were 
extubated in the operating room and had an uncomplicated 
course. Echocardiograms at 48 h, 1 and 2 months demonstrated 
excellent prosthetic valve function. There was a small para-
valvular leak in the first patient at 48 h, which was completely 
resolved at subsequent studies. The authors concluded that 
transapical transcatheter mitral valve implantation is techni-
cally feasible and can be performed safely (Cheung A et al, J 
Am Coll Cardiol 2014;64:1814-1819).
SECURITY Trial: In a Low-Risk Population, 6-Month 
Dual Antiplatelet Therapy After Second-Generation 
Drug Eluting Stent Implantation Appears Acceptable
In the SECURITY trial, 1,399 patients were randomi-zed 
to receive 6 (n=682) vs 12 months (n=717) dual antiplatelet 
therapy (DAPT). The primary endpoint (composite of cardiac 
50
HOSPITAL CHRONICLES 10(1), 2015
death, myocardial infarction -MI, stroke, definite or probable 
stent thrombosis, or Bleeding Academic Research Consortium 
-BARC type 3 or 5 bleeding at 12 months) was not different in 
the 2 groups. No differences were observed in the occurrence 
of the secondary endpoint (composite of cardiac death, MI, 
stroke, definite or probable stent thrombosis, or BARC type 
2, 3, or 5 bleeding at 12 and 24 months). Finally, no differ-
ences were observed in definite or probable stent thrombosis 
at 12 months (0.3% vs 0.4%) and between 12 and 24 months 
of follow-up (0.1% vs 0%). The authors concluded that in a 
low-risk population, the noninferiority hypothesis of 6 vs. 12 
months DAPT following second-generation DES implanta-
tion appears acceptable (Colombo A et al, J Am Coll Cardiol 
2014;64:2086-2097).
MESA Study: Positive Associations Between Baseline-
Corrected QT Intervals and Risks of Stroke, Heart 
Failure, and Cardiovascular Disease (CVD) Events in 
Middle-Aged Individuals Free of CVD at Baseline
The corrected baseline 12-lead ECG QT interval duration 
(QTc) was determined in 6,273 participants (mean age 62 ± 10 
years; 53% women) in MESA (Multi-Ethnic Study of Athero-
sclerosis). Cardiovascular events occurred in 291 participants 
over a mean follow-up of 8 ± 1.7 years. Each 10-ms increase 
in the baseline QTc was associated with incident heart failure 
(hazard ratio -HR: 1.25), CVD events (HR: 1.12), and stroke 
(HR: 1.19). There was no evidence of interaction with gender 
or ethnicity. The authors concluded that the QT interval was 
associated with incident cardiovascular events in middle-aged 
and older adults without prior CVD (Beinart R et al, J Am 
Coll Cardiol 2014;64:2111-2119).
ARREST-AF Study: Aggressive Risk Factor Reduction 
Improved Outcomes of AF Ablation by Reducing AF 
Burden and Severity Together With Favorable Changes 
in Cardiac Remodeling
Risk factor management (RFM) was offered to 149 of 
281 consecutive patients undergoing AF ablation who had a 
body mass index ≥27 kg/m2 and ≥1 cardiac risk factor. After 
AF ablation, RFM applied in 61 patients resulted in greater 
reductions in weight (p= 0.002) and blood pressure (p=0.006), 
and better glycemic control (p= 0.001) and lipid profiles (p= 
0.01). At follow-up, AF frequency, duration, symptoms, and 
symptom severity decreased more in the RFM group compared 
with the control group (n=88) (all p<0.001). Post-procedural 
arrhythmia-free survival was greater in RFM patients either 
with single or multiple procedures (p<0.001). On multivariate 
analysis, type of AF (p<0.001) and RFM (hazard ratio 4.8; 
p<0.001) were independent predictors of arrhythmia-free 
survival. The authors concluded that aggressive RFM improved 
the long-term success of AF ablation (Pathak RK et al, J Am 
Coll Cardiol 2014;64:2222-2231).
FOCUS Project: Polypill Strategy Improves Adherence 
Post Myocardial Infarction (MI)
Among 2,118 post-MI patients, in phase 1 of the FOCUS 
(Fixed-Dose Combination Drug for Secondary Cardiovascular 
Prevention) study, overall cardiovascular (CV) medication 
adherence, was 45.5%. In a multivariate analysis, the risk of 
being nonadherent was associated with younger age, depres-
sion, receiving complex medication regimen, poorer health 
insurance coverage, and a lower level of social support. In 
phase 2, 695 patients were randomized to a polypill (aspirin 
100 mg, simvastatin 40 mg, and ramipril 2.5, 5, or 10 mg) vs 
3 drugs given separately. Over 9 months, the polypill group 
showed improved adherence: 51% vs 41% (p=0.019; intention-
to-treat)/ ~66% vs 56% (p=0.012; per protocol). The authors 
concluded that for secondary prevention following acute MI, 
younger age, depression, and a complex drug regimen are 
associated with lower medication adherence, while a polypill 
strategy increased adherence (Castellano JM et al, J Am Coll 
Cardiol 2014;64:2071-2082).
Cardiac Deaths After Primary PCI Cluster in the First 
Month, While Later NonCardiac Deaths Prevail and 
Annual Cardiac Mortality Declines to <1.5%
Among 2,804 consecutive patients with STEMI (age 63 ± 
13 y, 72% males) treated with primary PCI and followed up 
for a median of 4.7 years, 717 patients died. Main causes of 
death within the first month were cardiogenic shock and anoxic 
brain injury after cardiac arrest. Age, culprit vessel size and 
flow, heart failure and diabetes were independent predictors 
of mortality. After the first month, noncardiac causes of death 
prevailed (65%; mainly malignancies and pulmonary diseases), 
while the annual cardiac mortality rate declined to <1.5%. 
1-month, 1-year, and 5-year all-cause (and cardiac) mortality 
rates were ~8%, 11%, & 23%, respectively. The authors con-
cluded that patients who survive the first month after STEMI 
treated with primary PCI have an excellent prognosis, with a 
<1.5% annual cardiac mortality risk, while noncardiac causes 
are responsible for the majority of later deaths (Pedersen F et 
al, J Am Coll Cardiol 2014;64:2101-2108).
Multicenter Evaluation of a Third-Generation Balloon-
Expandable Transcatheter Aortic Valve: New Valve 
Addresses Deficiencies of Earlier Transcatheter Valves
The SAPIEN 3 (Edwards Lifesciences Inc., Irvine, Cali-
fornia) transcatheter valve claims a low-profile delivery system 
that facilitates implantation and an external seal that mini-
mizes paravalvular regurgitation. The valve was evaluated in 
a prospective study of 150 patients at 16 sites in Europe and 
Canada (aged 83.6 ± 5.0 years; TCT score 7.4 ± 4.5% and 
logistic EuroSCORE 21.6 ± 12.3%; transfemoral approach in 
64.0%). At 30 days, paravalvular regurgitation was 0 to mild 
in ~96%. Transfemoral approach had low mortality (2.1%), 
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no disabling stroke (0.0%), and fully percutaneous access 
and closure in 96%. Nontransfemoral access was associated 
with higher rates of mortality (11.6%) and stroke (5.6%). 
The authors concluded that the new valve addresses major 
deficiencies of earlier valves in terms of ease of use, accuracy 
of positioning, and paravalvular sealing, with low rates of 
mortality and stroke via transfemoral access. (Webb J et al, J 
Am Coll Cardiol 2014;64:2235-2243).
ACCOAST-PCI Study: In Patients with NSTEMI, the 
Data Support Deferring a Loading Dose of Prasugrel 
until a Decision is Made About PCI
Among 4,033 patients with NSTEMI, 68.7% underwent 
PCI; 1,394 received pre-treatment with prasugrel (30-mg 
loading dose), and 1,376 received placebo. At the time of PCI, 
patients who received pre-treatment with prasugrel received 
an additional 30-mg dose of prasugrel, and those who received 
placebo received a 60-mg loading dose of prasugrel. The inci-
dence of the primary endpoint (composite of cardiovascular 
death, MI, stroke, urgent revascularization, or glycoprotein 
IIb/IIIa bailout) at 7 days in the pre-treatment group vs the no 
pre-treatment group was similar (13.1% vs 13.1%). Patients 
with thrombus on angiography had a 3-fold higher incidence 
of the primary endpoint than patients without thrombus. 
There was no impact of pre-treatment with prasugrel on the 
presence of thrombus before PCI or on occurrence of stent 
thrombosis after PCI. There was a 3-fold increase in major 
bleeding and a 6-fold increase in life-threatening bleeding 
with pre-treatment with prasugrel; same trends persisted in 
patients who had radial or femoral access even with use of a 
closure device. The authors concluded that these data support 
deferring treatment with prasugrel until a decision is made 
about revascularization in patients with NSTEMI undergoing 
angiography within 48 h of admission (Montalescot G et al, J 
Am Coll Cardiol 2014;64:2563-2571).
TRA 2°P-TIMI 50 Trial: Vorapaxar, a Novel 
Antiplatelet Agent Inhibiting Platelet Protease-
Activated Receptor (PAR)-1, Reduced Risk of Definite 
Stent Thrombosis Consistently Over Time not Modified 
by Background Use of DAPT
TRA 2°P-TIMI 50 (Trial to Assess the Effects of Vora-
paxar in Preventing Heart Attack and Stroke in Patients With 
Atherosclerosis-Thrombolysis In Myocardial Infarction 50) 
randomized 26,449 patients, with 14,042 (53%) having a his-
tory of a coronary stent implantation before randomization, 
and 449 patients receiving a coronary stent during the trial 
(total 14,491). During a median 2.5 years, there were 152 defi-
nite stent thrombosis (ST) events (majority - 92% occurring 
late). Vorapaxar reduced definite ST (1.1% vs 1.4%, hazard 
ratio - HR: 0.71; p= 0.037) consistently over time after PCI, 
not modified by diabetes, use of drug-eluting stents, or use 
of dual antiplatelet therapy (DAPT). Vorapaxar increased 
moderate/severe bleeding (HR: 1.57; p<0.001). The authors 
concluded that vorapaxar reduced definite ST (~1.4% at 
3 years) in stable patients with coronary stenting receiving 
standard antiplatelet therapy (Bonaca MP et al, J Am Coll 
Cardiol 2014;64:2309-2317).
PARTNER Trial: TAVI Confers Better Survival and 
Functional Status in Inoperable Patients with Severe 
Aortic Stenosis with Durable Benefit Over 3 Years, 
Albeit with High Residual Mortality
In the Placement of Aortic Transcatheter Valves (PART-
NER) study, among the 358 patients randomly assigned to 
transcatheter aortic valve implantation (TAVI) or standard 
therapy and all randomly assigned inoperable patients (n=449), 
including the randomized portion of the continued access study 
(n=91), the 3-year mortality rate in TAVI patients was 54.1% 
and 80.9% in the standard therapy group (P<0.001; hazard 
ratio-HR, 0.53; P<0.001). In survivors, there was significant im-
provement in NYHA functional class sustained at 3 years. The 
cumulative incidence of strokes at 3-year follow-up was 15.7% in 
TAVI patients vs 5.5% in patients with standard therapy (HR, 
2.81; P=0.012); however, the composite of death or strokes was 
significantly lower after TAVI vs standard therapy (57.4% vs 
80.9%, P<0.001; HR, 0.60; P<0.001). The authors concluded 
that TAVI resulted in better survival and functional status in 
inoperable patients with severe aortic stenosis with durable 
hemodynamic benefit on long-term follow-up. However, there 
is high residual mortality even in successfully treated TAVI 
patients (Kapadia SR et al, Circulation 2014; 130: 1483-1492).
A 5-Year United States PCI Experience (2005–2009):
Significant Impact of Annual Operator and 
Institutional Volume on PCI Outcomes
According with a Nationwide 5-year sample (2005-2009) 
of 457 498 percutaneous coronary interventions (PCIs) out 
of a total of 2 243 209 PCIs performed in the United States, 
in-hospital, all-cause mortality was 1.08%, and the overall 
complication rate was 7.10%. The primary (in-hospital mor-
tality) and secondary outcomes (in-hospital mortality and 
peri-procedural complications) of procedures performed by 
operators in 4th (>100 annual procedures), 3rd (45–100 proce-
dures), and 2nd quartile (16–44 procedures) were significantly 
less (P<0.001) when compared with those by operators in 
the 1st quartile (≤15 procedures). Similarly operators in the 
higher quartiles witnessed a significant reduction in length of 
hospital stay and cost (P<0.001). The authors concluded that 
overall in-hospital mortality after PCI was low. An increase 
in operator and institutional volume of PCI was found to be 
associated with a decrease in adverse outcomes, length of 
hospital stay, and cost of hospitalization (Badheka AO et al, 
Circulation 2014; 130: 1392-1406).
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ARIC Study: Most Patients With Incident Heart 
Failure (HF) Have Pre-Existing Overweight or Obesity 
and Once they Develop HF, they Have Lower Mortality 
Compared With Those With Prior Normal BMI /  
A Significant Component of this Obesity Paradox is 
Driven by Pre-Morbid Obesity
In the ARIC (Atherosclerosis Risk In Communities) study, 
among 1,487 patients with incident heart failure (HF), 35% 
were overweight and 47% were obese before HF diagnosis. 
Over 10-year follow-up after incident HF, 43% of patients died. 
Being pre-morbidly overweight (hazard ratio -HR: 0.72; p= 
0.004) or obese (HR: 0.70; p= 0.001) had a protective associa-
tion with survival compared with normal BMI. The authors 
concluded that patients who were overweight or obese before 
HF development have lower mortality after HF diagnosis 
compared with patients with normal body mass index (BMI) 
(Khalid U et al, J Am Coll Cardiol 2014;64:2743-2749).
RADAR-AF Trial: In Paroxysmal AF, Localized High-
Frequency Source Ablation (HFSA) was Inferior at 
6 Months but was as Efficacious as Circumferential 
Pulmonary Vein Isolation (CPVI) at 1 Year, While in 
Persistent AF, CPVI+ HFSA Offered no Incremental 
Value, With a Trend to More Complications
Among 232 patients (age 53±10 y), those with paroxysmal 
AF (n=115) were randomized to circumferential pulmonary 
vein isolation (CPVI) or localized high-frequency source abla-
tion (HFSA)-only and those with persistent AF (n=117) to 
CPVI or a combined ablation approach (CPVI+HFSA). In 
paroxysmal AF, HFSA failed to achieve noninferiority at 6 
months after a single procedure but, after redo procedures, 
was noninferior to CPVI at 12 months for freedom from AF 
with fewer serious adverse events. In persistent AF, there 
were no significant differences between treatment groups 
for AF recurrences, but CPVI+HFSA trended toward more 
serious adverse events (Atienza F et al, J Am Coll Cardiol 
2014;64:2455-2467).
Improved Survival After Out-of-Hospital Cardiac 
Arrest and Use of Automated External Defibrillators
According with a population-based cohort study of out-
of-hospital cardiac arrest (2006-2012), use of automated 
external defibrillators (AED) led to an increase in the rates of 
survival with favorable neurologic outcome (N=6133, 16.2% to 
19.7%; P for trend=0.021), albeit only in patients presenting 
with a shockable initial rhythm (N=2823; 29.1% to 41.4%; P 
for trend<0.001). Rates of AED use almost tripled during 
the study period (21.4% to 59.3%; P for trend <0.001), The 
authors concluded that increased AED use is associated with 
increased survival in patients with a shockable initial rhythm, 
recommending continuous efforts to introduce or extend AED 
programs (Blom MT et al, Circulation 2014; 130: 1868-1875).
Tetralogy of Fallot: Low Late Mortality at Prospective 
Follow-Up of 40 Years After Surgical Correction
According to a longitudinal cohort study of 136 out of 
144 patients with tetralogy of Fallot who underwent surgical 
repair at <15 years of age (1968-1980), cumulative survival 
was 72% after 40 years. Late mortality was due to heart failure 
and ventricular fibrillation. For 72 of 80 survivors participat-
ing in further in-hospital investigation, cumulative event-free 
survival was 25% after 40 years. Although systolic right and left 
ventricular function declined, peak exercise capacity remained 
stable. A previous shunt operation (hazard ratio-HR, 2.9), low 
temperature during surgery (HR 1.1), and early postoperative 
arrhythmias (HR 2.5) were found to predict late mortality. An 
increase in QRS duration and worsening exercise tolerance 
and ventricular dysfunction did not predict mortality. Insertion 
of a transannular patch was a predictor for late arrhythmias 
(HR, 4.0) (Cuypers J et al, Circulation 2014; 130: 1944-1953).
MADIT-CRT Trial: Left Ventricular Ejection Fraction 
Normalization in Cardiac Resynchronization Therapy 
(CRT) Decreases Risk of Ventricular Arrhythmias and 
Improves Clinical Outcomes
Among 752 patients in the MADIT-CRT trial a total of 
7.3% achieved left ventricular ejection fraction (LVEF) nor-
malization (>50%) over 2.2±0.8 years. The risk of ventricular 
tachyarrhythmias (VTA) was reduced in patients with LVEF 
>50% (hazard ratio -HR, 0.24; P=0.023) and LVEF of 36-50% 
(HR, 0.44; P<0.001). Among patients with LVEF >50%, only 
1 patient had VTA ≥200 bpm (HR, 0.16), none were shocked by 
the ICD, and 2 died of nonarrhythmic causes. The risk of HF 
or death was reduced with improvements in LVEF. A total of 6 
factors were associated with LVEF normalization, and patients 
with all factors present (n=42) did not experience VTAs. The 
authors concluded that patients who achieve LVEF normaliza-
tion (>50%) have very low absolute and relative risk of VTAs 
and a favorable clinical course within 2.2 years of follow-up. 
They recommend that these patients could be considered for 
downgrade from CRT-defibrillator to CRT-pacemaker at time 
of battery replacement if no VTAs have occurred (Ruwald 
MH et al, Circulation 2014; 130: 2278-2286).
X-VeRT: Oral Rivaroxaban an Effective & Safe Alter-
native to VKA/May Allow Prompter Cardioversion
Among 1504 patients with AF scheduled for cardiover-
sion, the primary efficacy outcome (stroke, TIA, peripheral 
embolism, MI, and cardiovascular death) occurred in 5 (2 
strokes) of 978 patients (0.51%) assigned to rivaroxaban and 
in 5 (2 strokes) of 492 patients (1.02%) receiving VKA (risk 
ratio – RR 0.50). In the rivaroxaban group, 4 (0.71%) patients 
experienced primary efficacy events following early (at 1-5 days) 
& 1 (0.24%) following delayed (3-8 weeks) cardioversion. In 
the VKA group, 3 (1.08%) had primary efficacy events fol-
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lowing early and 2 (0.93%) following delayed cardioversion. 
Rivaroxaban was associated with a significantly shorter time to 
cardioversion compared with VKAs (P<0.001). Major bleeding 
occurred in 6 (0.6%) in the rivaroxaban group and 4 patients 
(0.8%) in the VKA group (RR 0.76). The authors concluded 
that rivaroxaban is an effective and safe alternative to VKAs 
and may allow prompt cardioversion (Cappato R et al, Eur 
Heart J 2014; 35: 3346-3355).
AMIO-CAT trial: Short-Term Oral Amiodarone 
Treatment Following Ablation for Paroxysmal or 
Persistent AF did not Significantly Reduce AF 
Recurrence at 6-Months, but Prolonged Time to 
First Recurrence and Reduced Arrhythmia-Related 
Hospitalization and Cardioversion Rates
A total of 212 patients (median age 61 years) undergoing AF 
ablation were randomly assigned to 8 weeks of oral amiodar-
one or placebo post-procedurally. Recurrence was observed 
in 42/107 (39%) in the amiodarone group vs 48/99 (48%) in 
the placebo group (P = NS). The amiodarone group had 
significantly lower rate of arrhythmia-related hospitalizations 
(rate ratio = 0.43; P = 0.006) and cardioversions (rate ratio 
= 0.36; P = 0.0004) within the blanking period. The authors 
concluded that short-term oral amiodarone treatment follow-
ing AF ablation did not significantly reduce AF recurrence at 
6-months, but it more than halved atrial arrhythmia related 
hospitalization and cardioversion rates during the blanking 
period (Darkner S et al, Eur Heart J 2014; 35: 3356-3364).
ROCKET AF trial: Every Seventh Patient Had 
Significant Valvular Disease (SVD) Barring Mitral 
Stenosis & Prosthetic Valves / AF Patients With SVD 
Experienced the Same Stroke-Prevention Benefit from 
Oral Anticoagulants as did AF Patients Without SVD, 
but Bleeding Rates Were Higher With Rivaroxaban
In the ROCKET AF trial among 14 171 patients with non-
valvular AF, defined as the presence of AF in the absence of 
mitral stenosis or prosthetic valves, 2003 (14.1%) had significant 
valvular disease (SVD) (mitral regurgitation predominating 
at ~90%, followed by aortic regurgitation at 25%, and aortic 
stenosis at 11%, exceeding 100% due to cases with more than 
one type of valvular lesion). Patients with SVD were older 
and had more comorbidities. The rate of stroke or systemic 
embolism with rivaroxaban vs. warfarin was consistent among 
patients with SVD [2 vs. 2.4%; hazard ratio - HR 0.83) and 
without SVD (1.96 vs. 2.22%; HR 0.89; P=NS). However, 
rates of major and non-major clinically relevant bleeding with 
rivaroxaban vs warfarin were higher in patients with SVD (20% 
rivaroxaban vs 17% warfarin; HR 1.25) vs those without (14% 
in both), even when controlling for risk factors and potential 
confounders. In intracranial hemorrhage, there was no interac-
tion between patients with and without SVD where the overall 
rate was lower among those randomized to rivaroxaban. The 
authors concluded that many patients with ‘non-valvular atrial 
fibrillation’ have significant valve lesions. Their risk of stroke 
is similar to that of patients without SVD after controlling 
for stroke risk factors. Efficacy of rivaroxaban vs warfarin was 
similar in patients with and without SVD; however, the observed 
risk of bleeding was higher with rivaroxaban in patients with 
SVD but was the same among those without SVD (Breihardt 
G et al, Eur Heart J 2014; 35: 3377-3385).
ADVANCE-ON: In Type 2 Diabetes, Blood-Pressure 
Lowering but not Glucose Control Lowers Mortality or 
Macrovascular Events at 6 Years
In the Action in Diabetes and Vascular Disease: Preterax 
and Diamicron Modified Release Controlled Evaluation (AD-
VANCE) trial, antihypertensive therapy with perindopril and 
indapamide reduced mortality in patients with type 2 diabetes, 
but intensive glucose control, (glycated hemoglobin <6.5%), 
did not. Among 8494 out of 11,140 patients participating in the 
post-trial long-term (6-year) follow-up, reductions in the risk 
of death or cardiovascular death were attenuated in the group 
receiving anti-hypertensive therapy but remained significant at 
the end of the post-trial follow-up (hazard ratios 0.91, P=0.03 
and 0.88, P=0.04, respectively), while no differences were 
observed between the intensive-glucose-control group and the 
standard-glucose-control group. The authors concluded that 
antihypertensive therapy in diabetics is effective in reducing 
mortality, an effect attenuated but still evident over 6 years, 
while there is no evidence that intensive glucose control has 
any long-term benefits (Zoungas S et al, N Engl J Med 2014; 
371:1392-1406).
DAPT Study: 30 Instead of 12 Months of Dual 
Antiplatelet Therapy After Drug-Eluting Stents 
Reduces Stent Thrombosis and MACCE but Increases 
Risk of Bleeding
A total of 9961 patients receiving drug-eluting stents (DES) 
were randomized after 12 months to continue thienopyridine 
treatment or to receive placebo for another 18 months. Contin-
ued treatment with thienopyridine, as compared with placebo, 
reduced stent thrombosis (0.4% vs 1.4%; hazard ratio-HR, 0.29; 
P<0.001) and major adverse cardiovascular and cerebrovascu-
lar events (MACCE: death, myocardial infarction, or stroke) 
(4.3% vs 5.9%; HR, 0.71; P<0.001). The rate of bleeding was 
increased with continued thienopyridine treatment (2.5% vs 
1.6%, P=0.001). Risk of stent thrombosis and myocardial 
infarction increased in both groups during the 3 months after 
discontinuation of thienopyridine treatment. The authors 
concluded that dual antiplatelet therapy beyond 1 year after 
DES significantly reduced the risks of stent thrombosis and 
MACCE but was associated with an increased risk of bleeding 
(Mauri L et al, N Engl J Med 2014; 371:2155-2166).
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ARCTIC-Interruption Trial: No Benefit from Dual-
Antiplatelet Treatment Beyond 1 Year After DES
After 1 year of follow-up, 1259 patients having drug-eluting 
stent (DES) implantation were randomized to interruption of 
dual antiplatelet therapy (DAPT) while maintaining aspirin 
(interruption group, n=624) or to DAPT continuation for 6–18 
months (continuation group, n=635). After a median of 17 
months, the primary endpoint (death, MI, stent thrombosis, 
stroke, or urgent revasculari-sation) occurred in 27 (4%) 
patients in the interruption group and 24 (4%) patients in 
the continuation group (hazard ratio -HR 1.17; p=NS). Ma-
jor bleeding occurred more often in the continuation group 
(n=7, 1% vs n=1, <0·5%; HR 0.15; p=0.073). Major or minor 
bleedings were also more common in the continuation group 
compared with the interruption group (n=12, 2% vs n=3, 1%; 
HR 0.26; p=0.04). The authors concluded that extension of 
DAPT beyond 1 year after stenting with DES confers no ap-
parent benefit but instead harm when no event has occurred 
within the first year after stenting. N.B.: high-risk patients were 
not randomized in this study (Collet J et al, Lancet 2014;384 
(9954):1577–1585).
DALLAS Heart Study: HDL Cholesterol Efflux 
Capacity, a Functional Property of HDL, was 
Inversely Associated With Incident Atherosclerotic 
Cardiovascular Disease in a Population-Based Cohort 
Free from Cardiovascular Disease at Baseline
HDL cholesterol level, HDL particle concentration, and 
cholesterol efflux capacity were measured at baseline in 2924 
adults free from cardiovascular (CV) disease. Over a median 
follow-up of 9.4 years, cholesterol efflux capacity had minimal 
association with CV risk factors. Baseline HDL cholesterol 
level was not associated with CV events, whereas there was 
a 67% reduction in CV risk in the highest quartile of choles-
terol efflux capacity vs the lowest quartile (hazard ratio, 0.33). 
Adding cholesterol efflux capacity to traditional risk factors 
was associated with better discrimination and reclassification 
indexes. The authors concluded that cholesterol efflux capacity, 
a new biomarker featuring a key step in reverse cholesterol 
transport, was inversely associated with the incidence of CV 
events in a population-based cohort. This association persisted 
after adjustment for traditional CV risk factors, HDL choles-
terol level, and HDL particle concentration (Rohatgi A et al, 
N Engl J Med 2014;371:2383-93).
Similar Survival of Bioprosthetic and Mechanical 
Aortic Valves in Patients Aged 50 to 69 Years
Comparing survival and long-term outcome between bio-
prosthetic and mechanical valves in 4253 patients (aged 50-69 
years; propensity matching yielded 1001 patient pairs) who 
underwent aortic valve replacement (AVR) (1997-2004) over 
a median follow-up of 10.8 years, there were no differences 
in survival or stroke rates: actuarial 15-year survival 60.6% vs 
62.1%; 15-year cumulative incidence of stroke 7.7% vs 8.6%. 
The 15-year cumulative incidence of reoperation was higher 
in the bioprosthesis group (12.1% vs 6.9%; hazard ratio-HR, 
0.52). The 15-year cumulative incidence of major bleeding was 
higher in the mechanical prosthesis group (13.0% vs 6.6%; 
HR, 1.75). The 30-day mortality rate was 18.7% after stroke, 
9.0% after reoperation, and 13.2% after major bleeding. The 
authors concluded that among propensity-matched patients 
(50-69 years) who had AVR with bioprosthetic compared 
with mechanical valves, there was no significant difference 
in 15-year survival or stroke. The bioprosthetic valve group 
had more reoperations but lower major bleeding. Thus, bio-
prosthetic valves may be a reasonable choice in patients aged 
50 - 69 years (Chiang YP et al, JAMA 2014;312:1323-1329).
Nonobstructive Coronary Artery Disease (CAD) 
Compared With no Apparent CAD, was Associated 
with a Significantly Greater 1-Year Risk of Myocardial 
Infarction (MI) and All-Cause Mortality
Among 37 674 US veterans undergoing elective coronary 
angiography, 8384 (22%) had nonobstructive (≥1 stenosis 
≥20% but no stenosis ≥70%) CAD, and 20 899 patients (55%) 
had obstructive (any stenosis ≥70% or left main -LM stenosis 
≥50%) CAD. Within 1 year, 845 patients died and 385 were 
rehospitalized for MI. Among patients with no apparent (no 
stenosis >20%) CAD, the 1-year MI rate was 0.11% (n=8) 
and increased progressively by nonobstructive 1-vessel disease 
(1VD), 0.24%; 2VD, 0.56%; 3VD, 0.59%; obstructive 1VD, 
1.18%; 2VD, 2.18%; and 3VD or LM, 2.47%. One-year MI 
rates increased with increasing CAD extent. Relative to those 
with no apparent CAD, patients with non-obstructive 1VD 
had a hazard ratio (HR) for 1-year MI of 2; 2VD HR, 4.6; 
3VD HR, 4.5; obstructive 1VD HR, 9.0; 2VD HR, 16.5; and 
3VD or LM HR, 19.5. One-year mortality rates were associ-
ated with increasing CAD extent (1.38% in patients without 
apparent CAD to 4.30% in obstructive 3VD or LM). There 
was no significant association between nonobstructive 1VD or 
2VD and mortality, but there were significant associations with 
mortality for nonobstructive 3VD (HR, 1.6), obstructive 1VD 
(HR, 1.9), 2VD (HR, 2.8), and 3VD or LM (HR, 3.4). The 
authors concluded that among patients undergoing coronary 
angiography, nonobstructive CAD, compared with no apparent 
CAD, was associated with a greater 1-year risk of MI and all-
cause mortality (Maddox TM et al, JAMA 2014;312:1754-1763).
CHARGE Consortium: Association of LDL 
Cholesterol–Related Genetic Variants With Aortic 
Valve Calcium and Incident Aortic Stenosis
The prevalence of aortic valve calcium across the CHARGE 
cohorts (n=6942) was 32% (n = 2245). In the Malmö Diet and 
Cancer Study (MDCS) (n = 28 461), over a median follow-up 
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of ~16 years, aortic stenosis (AS) developed in 17 per 1000 
participants (n = 473) and aortic valve replacement for AS 
occurred in 7 per 1000 (n = 205). Plasma LDL-C, but not 
HDL-C or triglycerides (TG), was significantly associated with 
incident AS (hazard ratio -HR per mmol/L, 1.28; P =0.02; 
AS incidence: 1.3% and 2.4% in lowest and highest LDL-C 
quartiles, respectively). The LDL-C genetic risk scores (GRS), 
but not HDL-C or TG GRS, was associated with presence of 
aortic valve calcium in CHARGE (odds ratio - OR per GRS 
increment, 1.38; P =0.007) and with incident AS in MDCS 
(HR per GRS increment, 2.78; P = 0.02; AS incidence: 1.9% 
and 2.6% in lowest and highest GRS quartiles, respectively). 
The authors concluded that genetic predisposition to elevated 
LDL-cholesterol was associated with presence of aortic valve 
calcium and incidence of AS, supporting a causal association 
between LDL-C and aortic valve disease (Smith JG et al, JAMA 
2014;312:1764-1771).
ISAR-CLOSURE Trial: in Trans-Femoral Coronary 
Angiography, Vascular Closure Devices were Non-
Inferior to Manual Compression Regarding Access-Site 
Complications & Reduced Time to Hemostasis
Of 4524 patients undergoing transfemoral coronary an-
giography (2011-2014), 3015 were randomly assigned to a 
vascular closure device (VCD) group (intravascular VCD in 
1509, extravascular VCD in 1506) or manual compression 
group (n=1509). The primary end point (vascular complica-
tions at 30 days) was observed in 208 patients (6.9%) in the 
VCD group and 119 patients (7.9%) in the manual compres-
sion group (noninferior). Time to hemostasis was shorter in 
patients with VCD (1 minute), vs manual compression (10 
minutes) (P < 0.001). Time to hemostasis was shorter in patients 
with intravascular VCD (0.5 minute) vs extravascular VCD 
(2 minutes) (P <0.001) and closure device failure was also 
lower among those with intravascular vs extravascular VCD 
(80 patients - 5.3%, vs 184 patients - 12.2%; P < 0.001). The 
authors concluded that in patients undergoing transfemoral 
coronary angiography, VCDs were noninferior to manual 
compression in terms of vascular access-site complications and 
reduced time to hemostasis (Schulz-Schüpke S et al, JAMA 
2014;312:1981-1987).
PROTECT AF: Percutaneous Left Atrial Appendage 
Closure at Least Noninferior to Warfarin for Atrial 
Fibrillation at 3.8 Years of Follow-up
Among 707 patients with nonvalvular AF and >1 stroke 
risk factor randomized to left atrial appendage closure 
(n = 463) or warfarin (n = 244; target INR 2-3), over a mean 
follow-up of 3.8 years, there were 39 events (8.4%) in the 
device group and 34 events among 244 patients (13.9%) in 
the warfarin group (rate ratio, 0.60), meeting prespecified 
criteria for both noninferiority and superiority. Patients in the 
device group hadd lower rates of both cardiovascular mortality 
(3.7% vs 9%; hazard ratio -HR, 0.40; P =0.005) and all-cause 
mortality (12.3% vs 18.0%; HR, 0.66; P = 0.04). The authors 
concluded that after 3.8 years of follow-up among patients 
with nonvalvular AF at high risk for stroke, percutaneous 
LAA closure met criteria for both noninferiority and superior-
ity, compared with warfarin, for preventing stroke, systemic 
embolism, and cardiovascular death, as well as superiority 
for cardiovascular and all-cause mortality (Reddy VY et al, 
JAMA 2014;312:1988-1998).
HEAT PPCI Trial: Unfractionated Heparin Superior 
to Bivalirudin in Primary Percutaneous Coronary 
Intervention
Among 1812 patients undergoing emergency angiography 
randomly assigned to bivalirudin (n=905) or heparin (n=907), 
751 (83%) and 740 (82%), respectively, had primary percutane-
ous coronary intervention (PPCI). Rate of GP IIb/IIIa inhibitor 
use was similar in the 2 groups. The primary efficacy outcome 
(all-cause mortality, cerebrovascular accident, reinfarction, 
or unplanned target lesion revascularisation) occurred in 79 
(8.7%) patients in the bivalirudin group and 52 (5.7%) in the 
heparin group (absolute risk difference 3%; relative risk -RR 
1.52, p=0.01). The primary safety outcome (major bleeding) 
occurred in 32 (3.5%) in the bivalirudin group and 28 (3.1%) 
in the heparin group (0.4%; RR 1.15, p=NS). The authors 
concluded that compared with bivalirudin, heparin reduces the 
incidence of major adverse ischemic events in the setting of 
PPCI, with no increase in bleeding. Systematic use of heparin 
rather than bivalirudin would significantly reduce drug costs 
(Shahzad A et al, Lancet 2014;384(9957):1849–1858).
ACCORD Trial: Intensive Glycemic Control Reduces 
Risk of Ischemic Heart Disease
Over ~5 years (mean 3.7 years of active treatment plus a 
further mean 1.2 years), among 10 251 adults aged 40–79 years 
with type 2 diabetes and high mean glycated hemoglobin A1c 
(HbA1c) (8.3%), and risk factors for ischemic heart disease, 
assigned to intensive (target HbA1c <6%) or standard therapy 
(HbA1c 7–7.9%), myocardial infarction (MI) was less frequent 
in the intensive than in the standard therapy group during ac-
tive treatment (hazard ratio -HR 0.80; p=0.015) and overall 
(HR 0.84; p=0.02). Findings were similar for combined MI, 
revascularisation, and unstable angina (active treatment HR 
0.89, overall HR 0.87) and for coronary revascularisation alone 
(HR 0.84) and unstable angina alone (HR 0.81) during full 
follow-up. The authors concluded that glycemia is a modifiable 
risk factor for ischemic heart disease in middle-aged diabetics 
and other cardiovascular risk factors (Gerstein HC et al, Lancet 
2014; 384(9958):1936–1941).
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BIOSCIENCE: Ultrathin Strut Biodegradable Polymer 
Sirolimus-Eluting Stent Noninferior to Durable 
Polymer Everolimus-Eluting Stent
A total of 2119 patients with 3139 lesions were randomly as-
signed to biodegradable polymer sirolimus-eluting stents (SES) 
(1063 patients, 1594 lesions) or durable polymer everolimus-
eluting stents (EES) (1056 patients, 1545 lesions); 407 (19%) 
STEMI patients. Target lesion failure with biodegradable 
polymer SES (69 cases; 6·5%) was non-inferior to durable 
polymer EES (70 cases; 6.6%) at 1 year. No significant dif-
ferences were noted in rates of definite stent thrombosis: 9 
(0.9%) vs 4 (0.4%), rate ratio -RR 2.26, p=NS). Biodegradable 
polymer SES were associated with improved outcome com-
pared with durable polymer EES in the subgroup of patients 
with STEMI: 7 (3.3%) vs 17 (8.7%) (RR 0.38, p=0.024, p for 
interaction=0.014). The authors concluded that biodegradable 
polymer SES were non-inferior to durable polymer EES for the 
combined safety and efficacy outcome target lesion failure at 12 
months (Pilgrim T et al, Lancet 2014; 384 (9960):2111–2122).
Individual-Patient Data Meta-Analysis of 10 
Randomized Trials: No Benefit of β-Blockers in 
Patients With Heart Failure Plus Atrial Fibrillation
Individual-patient data from 10 randomized controlled 
trials (N= 18,254) of the comparison of β blockers vs placebo 
in heart failure, 13,946 (76%) having sinus rhythm and 3066 
(17%) atrial fibrillation, showed crude death rates over a mean 
follow-up of 1.5 years of 16% in patients with sinus rhythm 
and 21% in patients with atrial fibrillation. β-blocker therapy 
led to a significant reduction in all-cause mortality in patients 
with sinus rhythm (hazard ratio-HR 0.73; p<0·001), but not in 
patients with atrial fibrillation (HR 0.97; p=NS). The authors 
concluded that β blockers should not be used preferentially over 
other rate-control medications and not regarded as standard 
therapy to improve prognosis in patients with concomitant 
heart failure and atrial fibrillation (Kotecha D et al, Lancet 
2014; 384(9961):2235–2243).
Systematic Review and Meta-Analysis: Association of 
Atrial Fibrillation with Silent Cerebral Infarctions
A total of 11 studies including 5317 patients with mean 
ages from 50 to 83.6 years reported on the association between 
atrial fibrillation (AF) and silent cerebral infarctions (SCIs). 
When computed tomography (CT) and magnetic resonance 
imaging (MRI) studies were combined, AF was associated 
with SCIs in patients with no history of symptomatic stroke 
(odds ratio, 2.62). This association was independent of AF 
type (paroxysmal vs persistent). The results were not altered 
significantly when the analysis was restricted to studies that 
met at least 70% of the maximum possible quality score (odds 
ratio, 3.06). Seventeen studies reported the prevalence of SCIs. 
The overall prevalence of SCI lesions on MRI and CT among 
patients with AF was 40% and 22%, respectively. The authors 
concluded that atrial fibrillation is associated with more than a 
2-fold increase in the odds for silent cerebral infarction (Kal-
antarian S et al, Ann Intern Med 2014;161:650-658).
Danish Cohort Study: Risk for Serious Bleeding and 
Thromboembolism in Patients With Atrial Fibrillation 
(AF) Associated With use of Nonsteroidal Anti-
Inflammatory Drugs (NSAID)
Of 150,900 patients with AF (median age, 75 years; 47% 
female), 53,732 (35.6%) were prescribed an NSAID over 6.2 
years. There were 17,187 (11%) occurrences of serious bleeding 
and 19,561 (13%) events of thromboembolism. At 3 months, 
the absolute risk for serious bleeding within 14 days of NSAID 
exposure was 3.5 events per 1000 patients compared with 
1.5 events per 1000 patients without NSAID exposure. Use 
of NSAIDs was associated with increased absolute risks for 
serious bleeding and thromboembolism across all antithrom-
botic regimens and NSAID types. The authors concluded that 
physicians should exercise caution with NSAIDs in patients 
with AF (Lamberts M et al, Ann Intern Med 2014;161:690-698).
A Cohort Study: Renin–Angiotensin System Blockade 
Therapy Prolongs Survival After Surgical Aortic Valve 
Replacement (SAVR) for Severe Aortic Stenosis
Comparing 594 matched pairs among patients who were 
prescribed angiotensin-converting enzyme inhibitors or angio-
tensin-receptor blockers after SAVR for severe AS (1991-2010) 
(n=741) and those who did not receive these agents (n=1011), 
survival rates at 1, 5, and 10 years were significantly greater 
in the treated group than in the untreated group (99%, 90%, 
and 71% vs 96%, 78%, and 49%, respectively; P <0.001). The 
authors concluded that renin–angiotensin system blockade 
therapy is associated with increased survival rates in patients 
after SAVR for severe AS, dictating the need for a randomized 
trial to further confirm this finding (Goel SS et al, Ann Intern 
Med 2014;161:699-710).
Meta-Analysis: Coronary Artery Bypass Grafting 
(CABG) is Preferred Over Percutaneous Coronary 
Intervention (PCI) in Diabetics, Albeit with Increased 
Risk of Stroke
Meta-analysis of 40 randomized, controlled trials com-
paring PCI (with drug-eluting or bare-metal stents) with 
CABG in adults with diabetes with multivessel or left main 
coronary artery disease indicated that the primary outcome (a 
composite of all-cause mortality, nonfatal myocardial infarc-
tion, and stroke) increased with PCI (odds ratio -OR, 1.33). 
PCI resulted in increased mortality (OR, 1.44), no change in 
the number of myocardial infarctions (OR, 1.33), and fewer 
strokes (OR, 0.56). The authors concluded that CABG seems 
to be the preferred revascularization technique in diabetics, 
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however, because of residual uncertainties and increased risk 
for stroke with CABG, clinical judgment is required (Tu B et 
al, Ann Intern Med 2014;161:724-732).
Coronary Angiography and PCI via Radial vs Femoral 
Route on Uninterrupted Oral Anticoagulation with 
Warfarin: Fewer Bleeds with Radial Access in PCI
Among 255 consecutive patients in whom warfarin was 
continued who underwent coronary angiography (INR >1.8), 
97 also underwent percutaneous coronary intervention (PCI) 
(27% femoral vs 73% radial). No significant difference was 
seen in bleeds between femoral (2.8%) and radial (1.6%, 
P=NS) during coronary angiography alone. However, PCI 
via the femoral artery had more bleeding (19.2% vs 1.4%, 
P=0.005) and transfusions (15% vs 0%, P=0.004) than via 
the radial artery. Patients who underwent PCI using radial 
access were less likely to have any vascular or bleeding com-
plications (1% vs 23%, P=0.001) (Baker NC et al, Am Heart 
J 2014; 168:537–544).
Important Review and Other Articles
Scientific statement from AHA/ACC against the use of 
ECG as a screening tool for sudden death in the young, but 
in favor of widespread dissemination of automatic external 
defibrillators in the athletic field and elsewhere (Maron BJ 
et al, J Am Coll Cardiol 2014;64:1479-1514), Expert consen-
sus document (SCAI/AATS/ACC/STS) for transcatheter 
mitral valve repair (Tommaso CL et al, J Am Coll Cardiol 
2014;64:1515-1526), Thoracic aortic aneurysm (Goldfinger 
JZ et al, J Am Coll Cardiol 2014;64:1725-1739), Left ven-
tricular non-compaction (Arbustini E et al, J Am Coll Cardiol 
2014;64:1840-1850), 2014 ACC/AHA/AATS/ PCNA/SCAI/
STS Guideline Update for diagnosis and management of 
patients with stable ischemic heart disease (Fihn HD et al, J 
Am Coll Cardiol 2014;64:1929-1949), 2014 AHA/ACC/HRS 
Guideline for the management of patients with atrial fibrilla-
tion (January CT et al, J Am Coll Cardiol 2014;64:2246-2280), 
Vaccine for atherosclerosis (Shah PK et al, J Am Coll Cardiol 
2014;64:2779-2791), Post-thrombotic syndrome (Kahn SR et al, 
Circulation 2014;130:18 1636-1661), Transcatheter therapy of 
mitral regurgitation (Herrmann HC & Maisano F, Circulation 
2014;130:19 1712-1722), Pulmonary hypertension (Rich JD & 
Rich S, Circulation 2014;130:20 1820-1830), Rheumatic fever 
(Essop MR & Peters F, Circulation 2014, 130:24 2181-2188), 
2014 ESC Guidelines on pulmonary embolism (Konstantinides 
S, et al, Eur Heart J 2014; 35: 3033-3073), Management of 
antithrombotic therapy in AF patients presenting with ACS 
and/or undergoing PCI or valve interventions (Lip G et al, 
Eur Heart J 2014 35: 3155-3179), Acute pericarditis (LeWinter 
MM, N Engl J Med 2014;371:2410-2416), TAVI (Horne A et 
al, Am Hear J 2014;168:414-423),
Just-in (8/1/2015): the U.S. FDA approved Daiichi Sankyo’s 
new oral anticoagulant drug, edoxaban (Savaysa) for patients 
with non-valvular atrial fibrillation, and patients with deep 
vein thrombosis and/or pulmonary embolism.
9/1/2015: Portola Pharmaceuticals Inc announced that its 
experimental drug, andexanet alfa, met the main goal of revers-
ing the effect of rivaroxaban (Xarelto) and apixaban (Eliquis).
